Role of serum interleukin-6 in heart failure

Deokar, Smita A.; Dandekar, Sucheta; Shinde, Ganesh; Prabhu, Surekha; Patawardhan, Mugdha

doi:10.18203/2349-3933.ijam20183123

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interleukin-6 is the main determinant of CRP production [28] in the liver and is produced in monocytes, macrophages, endothelial cells, vascular smooth muscle cells, fibroblasts and heart myocytes under hypoxic stress [29]. Left ventricular dysfunction, liver or kidney damage caused by low cardiac output, hypoperfusion, hypoxia and venous congestion can stimulate the production of interleukin-6 and, therefore, CRP production [30]. It is also possible that the relationship between plasma CRP and heart failure is causal.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Weight Loss in Patients With Chronic Heart Failure and Redused Left Ventricular Ejection Fraction

Voitsekhovska

Воронков

2019

EUREKA: Health Sciences

View full text Add to dashboard Cite

Chronic heart failure (CHF) is a heterogeneous syndrome with a poor prognosis. Aim of the work – to define predictors of body weight (BW) loss in patients with CHF and a reduced left ventricular ejection fraction (LVEF). Materials and methods. 120 patients with stable CHF and LVEF ≤35 %, II-IV NYHA class were examined. Patients were divided into two groups according to the value of BW loss for 6 months: the first group - loss of BW <6 %, the second - ≥ 6 %. Results. Out of the 120 patients who were studied, a BW loss of ≥ 6 % occurred in 59 (49.2 %) patients. According to the results of binary logistic regression, predictors of BW loss of ≥6 % in patients with CHF and LVEF ≤ 35 % were: age, coronary heart disease, anaemia, and the number of hospitalizations over the last year. People with poorer quality of life, bigger number of points on the Beck depression scale and DEFS, with lower levels of physical activity and worse endothelium-dependent vasodilator response; higher sizes of the right atrium, right ventricle, and pulmonary artery systolic pressure, E / E '. Higher levels of C-reactive protein (CRP), uric acid are associated with a risk of losing BW≥6 %. Conclusions. Weight loss ≥ 6 % is observed in 49.2 % of patients with CHF and LVEF≤35 %. According to multivariate analysis, independent predictors of BW loss of ≥6 % in patients with CHF and LVEF≤35 % are age, CRP level, III-IV NYHA class, lower cholesterol levels, as well as lower rates of flow-dependent vasodilator response and hip circumference.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of Weight Loss in Patients With Chronic Heart Failure and Redused Left Ventricular Ejection Fraction

Voitsekhovska

Воронков

2019

EUREKA: Health Sciences

View full text Add to dashboard Cite

show abstract

“…The significantly increased serum interleukin-6 (median [IQR] 14.3[26.2] pg/mL) in heart failure patients as compared to age and sex-matched controls (median [IQR] 0[2.4] pg/mL). The authors showed an increased level of interleukin-6 in heart failure patients played an important role as a pro-inflammatory marker in the development of cardiovascular disease including heart failure [34].…”

Section: Interleukin-6mentioning

confidence: 99%

Biomarkers of Metabolic Syndrome in Cardiomyopathy: A Leading Cause of Heart Failure

Sharif¹,

Rafaqat²,

Naz³

2024

New Insights on Cardiomyopathy

View full text Add to dashboard Cite

Cardiomyopathy is a disease of the heart muscle, which makes the muscles harder to pump blood to the rest of the body leading to heart failure. The main types of cardiomyopathies include dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, arrhythmogenic right ventricular dysplasia, restrictive cardiomyopathy, and Takotsubo cardiomyopathy. On the other hand, Metabolic syndrome (MetS) is the clustering of different medical conditions, which requires at least three of the five following diseases. These diseases are high blood sugar, high blood pressure, high serum triglycerides, low serum high-density lipoprotein, and central obesity. The risk of developing type 2 diabetes and cardiovascular disease associated with metabolic syndrome. In MetS, many different biomarkers are used in the early detection and risk stratification of MetS patients. It includes adiponectin, leptin, interleukin 6, tumor necrosis factor-alpha, uric acid, interleukin 10, ghrelin, adiponectin, paraoxonase, oxidized low-density lipoprotein, and plasminogen activator inhibitor-1. This chapter provides an overview and focuses on the basic role of major biomarkers of metabolic syndrome in the pathogenesis of different types of cardiomyopathies, which mainly highlights recent pathophysiological aspects in the development and progress of cardiomyopathy which is the leading cause of heart failure. In conclusion, biomarkers of metabolic syndrome play a significant role in the development and progress of cardiomyopathy which is the leading cause of heart failure.

show abstract

Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction

Bahrami,

Aromolaran,

Aromolaran

2024

IJMS

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is increasing at an alarming rate worldwide, with limited effective therapeutic interventions in patients. Sudden cardiac death (SCD) and ventricular arrhythmias present substantial risks for the prognosis of these patients. Obesity is a risk factor for HFpEF and life-threatening arrhythmias. Obesity and its associated metabolic dysregulation, leading to metabolic syndrome, are an epidemic that poses a significant public health problem. More than one-third of the world population is overweight or obese, leading to an enhanced risk of incidence and mortality due to cardiovascular disease (CVD). Obesity predisposes patients to atrial fibrillation and ventricular and supraventricular arrhythmias—conditions that are caused by dysfunction in the electrical activity of the heart. To date, current therapeutic options for the cardiomyopathy of obesity are limited, suggesting that there is considerable room for the development of therapeutic interventions with novel mechanisms of action that will help normalize sinus rhythms in obese patients. Emerging candidates for modulation by obesity are cardiac ion channels and Ca-handling proteins. However, the underlying molecular mechanisms of the impact of obesity on these channels and Ca-handling proteins remain incompletely understood. Obesity is marked by the accumulation of adipose tissue, which is associated with a variety of adverse adaptations, including dyslipidemia (or abnormal systemic levels of free fatty acids), increased secretion of proinflammatory cytokines, fibrosis, hyperglycemia, and insulin resistance, which cause electrical remodeling and, thus, predispose patients to arrhythmias. Furthermore, adipose tissue is also associated with the accumulation of subcutaneous and visceral fat, which is marked by distinct signaling mechanisms. Thus, there may also be functional differences in the effects of the regional distribution of fat deposits on ion channel/Ca-handling protein expression. Evaluating alterations in their functional expression in obesity will lead to progress in the knowledge of the mechanisms responsible for obesity-related arrhythmias. These advances are likely to reveal new targets for pharmacological modulation. Understanding how obesity and related mechanisms lead to cardiac electrical remodeling is likely to have a significant medical and economic impact. Nevertheless, substantial knowledge gaps remain regarding HFpEF treatment, requiring further investigations to identify potential therapeutic targets. The objective of this study is to review cardiac ion channel/Ca-handling protein remodeling in the predisposition to metabolic HFpEF and arrhythmias. This review further highlights interleukin-6 (IL-6) as a potential target, cardiac bridging integrator 1 (cBIN1) as a promising gene therapy agent, and leukotriene B4 (LTB4) as an underappreciated pathway in future HFpEF management.

show abstract

Role of serum interleukin-6 in heart failure

Cited by 3 publications

References 24 publications

Predictors of Weight Loss in Patients With Chronic Heart Failure and Redused Left Ventricular Ejection Fraction

Predictors of Weight Loss in Patients With Chronic Heart Failure and Redused Left Ventricular Ejection Fraction

Biomarkers of Metabolic Syndrome in Cardiomyopathy: A Leading Cause of Heart Failure

Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction

Contact Info

Product

Resources

About